A randomised control trial of omega-3 fatty acid on platelet and endothelial function in patients with peripheral arterial disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001332-69-GB

Enrollment

150

Registered

2005-05-04

Start date

2005-07-14

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intermittent claudication

Interventions

Trade Name: OMACOR Product Name: OMACOR Product Code: N/A Pharmaceutical Form: Capsule* INN or Proposed INN: (46%)Eicosapentaenoic acid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients must be able to give fully informed consent, have an ABPI =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients with critical limb ischaemia, liver impairment, abnormal platelet count, diabetes mellitusand those on clopidogrel, warfarin and NSAIDS

Design outcomes

Primary

Measure	Time frame
Main Objective: In patients with peripheral arterial disease, to assess the effects of omega-3 fatty acids on 1) platelet function 2) markers of endothelial activation ;Secondary Objective: In patients with peripheral arterial disease,to assess the effects of omega 3 fatty acids on flow mediated dilatation; Primary end point(s): 1) platelet function as assessed by flow cytometry and ultegra RPFA 2) endothelial function as assessed by Von Willebrand Factor	—

Measure

Time frame

Main Objective: In patients with peripheral arterial disease, to assess the effects of omega-3 fatty acids on 1) platelet function 2) markers of endothelial activation ;Secondary Objective: In patients with peripheral arterial disease,to assess the effects of omega 3 fatty acids on flow mediated dilatation; Primary end point(s): 1) platelet function as assessed by flow cytometry and ultegra RPFA 2) endothelial function as assessed by Von Willebrand Factor

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026